Suchergebnisse - "Scheen, André"

PubPharm (531)

1

First-line treatment of hypercholesterolemia : start with statin monotherapy or ezetimibe-statin combination ?

enthalten in: Revue medicale de Liege | 2024

von Scheen, A. | Wallemacq, C. | Lancellotti, P.

2

Patient with type 2 diabetes and coronary heart disease developing heart failure

enthalten in: Revue medicale de Liege | 2024

von Scheen, A. | Paquot, N. | Lancellotti, P.

3

Don't neglect metabolic syndrome

enthalten in: Revue medicale de Liege | 2024

von Scheen, A. | Luyckx, F. | Esser, N. | +1

4

GLP-1 receptor agonists in type 2 diabetes : paradoxical real-life underuse in patients with atherosclerotic cardiovascular disease

enthalten in: Revue medicale de Liege | 2024

von Scheen, A.

5

Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes : A narrative review

enthalten in: Diabetes & metabolism | 2024

von Scheen, A.

6

Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment

enthalten in: Revue medicale de Liege | 2024

von Lancellotti, P. | de Marneffe, N. | Scheen, A.

7

Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes

enthalten in: Revue medicale de Liege | 2023

von Scheen, A. | Delanaye, P.

8

Pneumococcal vaccination among at-risk groups with comorbidities : guidelines from the "Belgian Superior Health Council" and reimbursement criteria

enthalten in: Revue medicale de Liege | 2023

von Scheen, A. | Louis, R. | Lancellotti, P. | +3

9

Evolocumab (Repatha®) : new therapy ofhypercholesterolaemia for secondary prevention of atherosclerotic disease

enthalten in: Revue medicale de Liege | 2023

von Scheen, A. | Wallemacq, C. | Lancellotti, P.

10

Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents

enthalten in: The lancet. Diabetes & endocrinology | 2023

von Scheen, A.

CommentOn: Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. - PMID 37499675

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[54]